A Phase 1 Study of ASP1012 in Solid Tumors

Study Description

A Study to Evaluate the Safety and Dosage of an Experimental Cancer Treatment Called ASP1012 in Adults with Advanced Solid Tumors

Study Details

Registry ID:

NCT06171178

Conditions:

Solid Tumor

Phase:

Phase 1

Target Enrollment:

15 participants

Start Date:

May 15, 2024

Age Range:

18–999 years

Healthy Volunteers:

No

Study Locations (8 sites)

• Roswell Park Cancer Institute
  Buffalo, New YorkUnited States, United States
• Emory Winship Cancer Institute
  Atlanta, GeorgiaUnited States, United States
• Gabrail Cancer and Research Center
  Canton, OhioUnited States, United States
• Karmanos Cancer Institute
  Detroit, MichiganUnited States, United States
• University of Iowa Hospitals
  Iowa City, IowaUnited States, United States
• Mary Crowley Cancer Research
  Dallas, TexasUnited States, United States
• Hoag Memorial Hospital Presbyterian
  Newport Beach, CaliforniaUnited States, United States
• The Angeles Clinic and Research Institute
  Los Angeles, CaliforniaUnited States, United States

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →